Jyong Biotech Ltd. Ordinary Shares (MENS)vsBeiGene, Ltd. (ONC)
MENS
Jyong Biotech Ltd. Ordinary Shares
$2.09
+4.50%
HEALTHCARE · Cap: $152.06M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
MENS
Avoid17
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MENS.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MENS
The strongest argument for MENS centers on Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : MENS
The primary concerns for MENS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
MENS profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 17/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Jyong Biotech Ltd. Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Jyong Biotech Ltd. (ticker: MENS) is an innovative biotechnology company specializing in the development of cutting-edge therapeutic solutions for cancer and autoimmune disorders. Leveraging advanced genomics and molecular biology research, the firm boasts a promising pipeline of therapies supported by a strong intellectual property portfolio. Strategic partnerships within the biopharmaceutical sector further enhance its market position, enabling Jyong Biotech to capitalize on emerging opportunities while maintaining a steadfast commitment to scientific excellence and patient-centric care, ensuring a substantial impact on healthcare advancements.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?